MPLT
MapLight Therapeutics, Inc.
6.80$
-10.6%
vs. previous close
Closing price · As of: Nov 2, 2026
Ownership
Ownership Structure
Who owns MapLight Therapeutics, Inc. (MPLT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 29.9% of the shares are freely tradable; institutional investors hold 56.0%.
Institutional ownership
?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
56.0%
Insiders
?Share of the stock held by the executives, founders and major shareholders of the company itself.
51.2%
Float
?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
29.9%
Short % of float
?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
9.8%
Shares Outstanding
?Total number of shares issued. Price times share count gives market cap.
53Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Novo A/S | 6.63 | 3,686,622 | +0.0 | 06/30/2026 |
| FCPM III SERVICES BV | 5.81 | 3,226,400 | +0.0 | 06/30/2026 |
| T. Rowe Price Investment Management,Inc. | 5.01 | 2,781,728 | -0.7 | 06/30/2026 |
| The Goldman Sachs Group Inc | 3.51 | 1,948,312 | -2.3 | 06/30/2026 |
| T. Rowe Price Associates, Inc. | 2.56 | 1,422,935 | +1,162.5 | 06/30/2026 |
| BlackRock Inc | 1.84 | 1,025,134 | -23.5 | 06/30/2026 |
| Nan Fung Group Holdings Ltd | 1.75 | 971,253 | +0.0 | 06/30/2026 |
| 5AM Venture Management, LLC | 1.71 | 950,011 | +0.0 | 06/30/2026 |
| Sanofi | 1.64 | 912,041 | +0.0 | 06/30/2026 |
| State Street Corp | 1.53 | 852,150 | +151.3 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Catalyst4, Inc. | 10% Owner | 25,306,689 | 172,085,485 $ | Aug 14, 2026 | indirect |
| Kroeger Christopher A. | Chief Executive Officer | 1,195,909 | 8,132,181 $ | Oct 15, 2026 | direct |
| Foff Erin Pennock | Chief Medical Officer | 296,906 | 2,018,961 $ | Oct 15, 2026 | direct |
| Lillie James Woodruff | Chief Scientific Officer | 198,597 | 1,350,460 $ | Oct 15, 2026 | direct |
| Kreitzer Anatol | Chief Discovery Officer | 168,678 | 1,147,010 $ | Oct 15, 2026 | direct |
| Gillis Jonathan | CAO and Interim CFO | 142,315 | 967,742 $ | Oct 15, 2026 | direct |
| Hanson Kristopher | General Counsel | 128,024 | 870,563 $ | Oct 15, 2026 | direct |
| Cox Troy | Director | 15,620 | 106,216 $ | Jul 28, 2026 | indirect |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Kreitzer Anatol | Chief Discovery Officer | Sell | 12,248 | 7.84 | 96,024 |
| Oct 15, 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 15,355 | 8.08 | 124,068 |
| Oct 15, 2026 | Hanson Kristopher | General Counsel | Sell | 9,020 | 8.08 | 72,882 |
| Oct 15, 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | 11,513 | 8.08 | 93,025 |
| Oct 15, 2026 | Gillis Jonathan | CAO and Interim CFO | Sell | 10,167 | 8.08 | 82,149 |
| Oct 15, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 73,691 | 8.08 | 595,423 |
| Sep 16, 2026 | Hanson Kristopher | General Counsel | Sell | 16,509 | 11.67 | 192,660 |
| Aug 17, 2026 | Kreitzer Anatol | Chief Discovery Officer | Other | 6,020 | 0.00 | – |
| Aug 17, 2026 | Foff Erin Pennock | Chief Medical Officer | Other | 13,360 | 0.00 | – |
| Aug 17, 2026 | Hanson Kristopher | General Counsel | Other | 7,730 | 0.00 | – |
| Aug 17, 2026 | Lillie James Woodruff | Chief Scientific Officer | Other | 7,730 | 0.00 | – |
| Aug 17, 2026 | Gillis Jonathan | CAO and Interim CFO | Other | 2,222 | 0.00 | – |
| Aug 17, 2026 | Gillis Jonathan | CAO and Interim CFO | Other | 6,020 | 0.00 | – |
| Aug 17, 2026 | Kroeger Christopher A. | Chief Executive Officer | Other | 23,145 | 0.00 | – |
| Aug 14, 2026 | Catalyst4, Inc. | 10% Owner | Buy | 4,400,000 | 11.38 | 50,072,000 |
| Aug 3, 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | 22,082 | 12.54 | 276,908 |
| Jul 30, 2026 | Catalyst4, Inc. | 10% Owner | Buy | 1,000,000 | 13.00 | 13,000,000 |
| Jul 29, 2026 | Catalyst4, Inc. | 10% Owner | Buy | 3,000 | 12.63 | 37,890 |
| Jul 28, 2026 | Catalyst4, Inc. | 10% Owner | Buy | 65,137 | 11.69 | 761,393 |
| Jul 28, 2026 | Catalyst4, Inc. | 10% Owner | Buy | 141,088 | 10.74 | 1,515,511 |
| Jul 28, 2026 | Cox Troy | Director | Buy | 15,620 | 9.52 | 148,702 |
| Jul 17, 2026 | Kreitzer Anatol | Chief Discovery Officer | Sell | 200 | 38.39 | 7,678 |
| Jul 17, 2026 | Kreitzer Anatol | Chief Discovery Officer | Sell | 14,140 | 37.70 | 533,078 |
| Jul 17, 2026 | Kreitzer Anatol | Chief Discovery Officer | Sell | 2,833 | 37.05 | 104,963 |
| Jul 17, 2026 | Gillis Jonathan | CAO and Interim CFO | Sell | 900 | 38.17 | 34,353 |
| Jul 17, 2026 | Gillis Jonathan | CAO and Interim CFO | Sell | 16,969 | 37.61 | 638,204 |
| Jul 17, 2026 | Gillis Jonathan | CAO and Interim CFO | Sell | 600 | 36.51 | 21,906 |
| Jul 17, 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 3,656 | 37.90 | 138,562 |
| Jul 17, 2026 | Hanson Kristopher | General Counsel | Sell | 1,130 | 37.90 | 42,827 |
| Jul 17, 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | 2,077 | 37.90 | 78,718 |
| Jul 17, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 16,779 | 37.90 | 635,924 |
| Jul 16, 2026 | Kreitzer Anatol | Chief Discovery Officer | Sell | 1,592 | 37.44 | 59,604 |
| Jul 16, 2026 | Kreitzer Anatol | Chief Discovery Officer | Sell | 7,464 | 36.66 | 273,630 |
| Jul 16, 2026 | Gillis Jonathan | CAO and Interim CFO | Sell | 1,476 | 37.44 | 55,261 |
| Jul 16, 2026 | Gillis Jonathan | CAO and Interim CFO | Sell | 6,979 | 36.66 | 255,850 |
| Jul 16, 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 19 | 37.96 | 721 |
| Jul 16, 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 5,865 | 37.26 | 218,530 |
| Jul 16, 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | 9,163 | 36.46 | 334,083 |
| Jul 16, 2026 | Hanson Kristopher | General Counsel | Sell | 11 | 37.96 | 418 |
| Jul 16, 2026 | Hanson Kristopher | General Counsel | Sell | 3,331 | 37.26 | 124,113 |
| Jul 16, 2026 | Hanson Kristopher | General Counsel | Sell | 4,776 | 36.45 | 174,085 |
| Jul 16, 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | 12 | 37.96 | 456 |
| Jul 16, 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | 3,526 | 37.26 | 131,379 |
| Jul 16, 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | 5,009 | 36.45 | 182,578 |
| Jul 16, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 92 | 37.96 | 3,492 |
| Jul 16, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 28,091 | 37.26 | 1,046,671 |
| Jul 16, 2026 | Kroeger Christopher A. | Chief Executive Officer | Sell | 40,899 | 36.46 | 1,491,178 |
| Jul 15, 2026 | Kreitzer Anatol | Chief Discovery Officer | Sell | 4,510 | 36.94 | 166,599 |
| Jul 15, 2026 | Kreitzer Anatol | Chief Discovery Officer | Sell | 5,545 | 36.13 | 200,341 |
| Jul 15, 2026 | Gillis Jonathan | CAO and Interim CFO | Sell | 4,699 | 36.94 | 173,581 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.